BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    OSTEOVATION EX 5CC INJECT FORMULA

    MDR report key: 9965300 · Received April 15, 2020

    Report

    Report Number
    2027754-2020-00003
    Event Type
    Malfunction
    Date Received
    April 15, 2020
    Date of Event
    April 8, 2020
    Report Date
    April 8, 2020
    Manufacturer
    OSTEOMED, LLC
    Product Code
    PBU
    UDI-DI
    00813845020023
    PMA / PMN Number
    K051123
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL

    Narratives

    Additional Manufacturer Narrative · 0

    THE OSTEOVATION EX INJECTABLE, 390-0005, OF LOT #1128523 USED IN THIS EVENT WAS NOT RETURNED AS IT WAS IMPLANTED. A PRODUCT REPRESENTATIVE WAS ON SITE AND ATTESTED THAT THE MIXING OF THE OSTEOVATION WAS PERFORMED CORRECTLY AND BOTH HE AND THE DOCTOR OBSERVED OSTEOVATION SETTING PRIOR TO WOUND CLOSURE. NO EVALUATION OF PHYSICAL DEVICE WAS ABLE TO BE PERFORMED. PER DOCTOR'S FEEDBACK POST-OP THE DECISION WAS MADE TO CLOSE THE WOUND WITH THE IMPLANTED BONE VOID FILLER AS IT HAD BEGUN TO HARDEN. THIS HARDENING IS INDICATIVE OF AN IRREVERSIBLE CHEMICAL REACTION THAT SETS BONE VOID FILLER MADE FROM ALFA-TRICALCIUM PHOSPHATE (ALFA-TCP). THE SURGEON, VIA EMAIL, ULTIMATELY CONCLUDED THAT THE PATIENT'S HISTORY OF ANKLE SURGERIES AND INFECTION WERE MORE LIKELY THE CAUSE OF POST-OPERATIVE ISSUES THAN THE IMPLANTATION OF OSTEOVATION. THE INFECTION WAS TREATED SUCCESSFULLY WITH ANTIBIOTICS. THE DOCTOR INDICATED THAT THE INFECTION WAS OF AN UNKNOWN ORIGIN. THE ROOT CAUSE OF THIS COMPLAINT IS UNDETERMINED. THE DHR WAS REVIEWED AND FOUND NO ISSUES THAT WOULD CONTRIBUTE TO THE ROOT CAUSE. IN ADDITION, A 2-YEAR REVIEW OF CAPAS AND NCS WAS UNDERTAKEN AND NONE WERE IDENTIFIED THAT HAD A ROOT CAUSE SIMILAR TO THIS CASE. THE CALCIUM PHOSPHATE (CAP) IMPACTABLE (REP 11857-AL) AND INJECTABLE DESIGN FAILURE MODES AND EFFECTS ANALYSIS, COVERS THE RISK OF AN INFECTION DUE TO A NON-STERILE DEVICE. THIS RISK HAS A RATING OF 3, WHICH PER THE SK RISK ANALYSIS PROCEDURE, IS "CRITICAL" (POTENTIAL OF DEATH OR SERIOUS INJURY). THE LIKELIHOOD HAS A VALUE OF 2, WHICH IS DEFINED "UNLIKELY" (BETWEEN ONE IN A MILLION AND ONE IN TEN THOUSAND). THIS GIVES A FINAL RISK RATING OF 6, WHICH IS "ACCEPTABLE" PER THE SAME PROCEDURE. THE CRANIOSCULPT FLOW INSTRUCTIONS FOR USE (LBL 10628-AJ), LISTS CONTRAINDICATIONS SUCH AS USE IN AN INFECTED OR SUSPECTED INFECTION SITE, IMPLANTATION INTO AREAS WHERE BONE TISSUE IS NOT VIABLE AND USE ON PATIENTS WHO HAVE NOT REACHED SKELETAL MATURITY. IN ADDITION, THE IFU STATES, "STERILE PRODUCT PACKAGING SHOULD BE INSPECTED FOR FLAWS AND INTEGRITY PRIOR TO OPENING. IN THE PRESENCE OF SUCH A FLAW, THE PRODUCT MUST BE CONSIDERED NON-STERILE AND APPROPRIATELY DISCARDED." THIS ISSUE WILL BE MONITORED THROUGH ROUTINE TRENDING.

    Description of Event or Problem · 0

    ON (B)(6) 2020 OSTEOMED WAS NOTIFIED OF A PATIENT PRESENTING OPEN WOUNDS ON SURGICAL SITE (RIGHT ANKLE). PATIENT HAS HAD 4 SURGERIES IN THE PAST YEAR ON THE ANKLE. THE PATIENT DID ORIGINALLY HAVE OSTEOMED SCREWS IN THE RIGHT ANKLE AND THE DOCTOR FELT THERE MAY NEED TO BE A REVISION AND AN ADDITION OF A PLATE FOLLOWING THE 3RD SURGERY. THE REVISION WAS NOT DUE TO A COMPLAINT OR ISSUE WITH OSTEOMED SCREWS IMPLANTED. THERE WERE NO ISSUES TO REPORT ON THE PRODUCTS; THE PATIENT HAD SEPARATION AND ISSUES HEALING UNRELATED TO THE SURGERY OR THE SCREWS. ON JANUARY 8TH THE SCREWS WERE REMOVED AND THE EXTREMILOCK ANKLE PLATING SYSTEM WAS IMPLANTED ALONG WITH THE OSTEOVATION PRODUCT. OSTEOVATION EX 5CC, INJECT FORMULA (PART 390-0005) WAS USED TO BACKFILL A VOID, DUE TO MISSING BONE. OSTEOVATION WAS NOT SETTING IN A TIMELY MANNER AND THE SALES REPRESENTATIVE IN THE SURGERY TRIED TO CONTACT OSTEOMED SALES SUPPORT. THE PRODUCT MANAGER HELPED TROUBLESHOOT SOME STEPS TO HELP SETTING. WARM COMPRESSION WITH WARM SALINE FOR ABOUT 10 MINUTES WERE USED. THEN, LOWERED TOURNIQUET WAS USED TO INCREASE HEAT. OSTEOVATION BEGAN TO SET AND 2 DOCTORS MADE THE DECISION TO CLOSE AFTER THE OSTEOVATION WAS NO LONGER RUNNY. THE SALES REPRESENTATIVE SPOKE WITH THE DOCTOR IN (B)(6) 2020 AND THE DOCTOR REPORTED NO ISSUES WITH THE PATIENT OR PATIENT'S HEALING. IT WAS MENTIONED THAT ON X-RAYS WAS SHADOW NEAR THE OSTEOVATION IMPLANT SITE BUT FELT NO CONCERN WITH THE PRODUCT. PATIENT CALLED DOCTOR AND FOLLOWED UP IN OFFICE ON (B)(6) 2020 DUE TO OPEN WOUNDS AND TROUBLE HEALING. THE PHYSICIAN TREATED WOUNDS AND REMOVED LIQUID AND WHAT APPEARED TO BE SOLID FRAGMENTS OF THE OSTEOVATION PRODUCT. THE DOCTOR CALLED THE SALES REPRESENTATIVE AFTER VISITING WITH PATIENT. THE DOCTOR INFORMED THAT THE PATIENT WAS PRESENTING WITH OPEN WOUNDS ON SURGICAL SITE AND HAD OBSERVED OSTEOVATION OOZING OUT OF WOUNDS. THE PATIENT HAD REMOVED SEVERAL REMNANTS OF OSTEOVATION AS WELL.

    Additional Manufacturer Narrative · 1

    OSTEOMED LLC IS A DISTRIBUTOR OF BONE VOID FILLER KITS AND SKELETAL KINETICS LLC IS THE LEGAL MANUFACTURER. OSTEOMED HAS INITIATED A RECALL ON CERTAIN BONE VOID FILLER KITS AND ALSO CEASED DISTRIBUTION OF THE PRODUCT ALTOGETHER. WE ARE CONDUCTING A THOROUGH INVESTIGATION OF THIS COMPLAINT AND WILL UPDATE FDA WHEN CONCLUDED.

    Description of Event or Problem · 1

    ON (B)(6) 2020 OSTEOMED WAS NOTIFIED OF A PATIENT PRESENTING OPEN WOUNDS ON SURGICAL SITE (RIGHT ANKLE). PATIENT HAS HAD 4 SURGERIES IN THE PAST YEAR ON THE ANKLE. THE PATIENT DID ORIGINALLY HAVE OSTEOMED SCREWS IN THE RIGHT ANKLE AND THE DOCTOR FELT THERE MAY NEED TO BE A REVISION AND AN ADDITION OF A PLATE FOLLOWING THE 3RD SURGERY. THE REVISION WAS NOT DUE TO A COMPLAINT OR ISSUE WITH OSTEOMED SCREWS IMPLANTED. THERE WERE NO ISSUES TO REPORT ON THE PRODUCTS; THE PATIENT HAD SEPARATION AND ISSUES HEALING UNRELATED TO THE SURGERY OR THE SCREWS. ON (B)(6) THE SCREWS WERE REMOVED AND THE EXTREMILOCK ANKLE PLATING SYSTEM WAS IMPLANTED ALONG WITH THE OSTEOVATION PRODUCT. OSTEOVATION EX 5CC, INJECT FORMULA (PART 390-0005) WAS USED TO BACKFILL A VOID, DUE TO MISSING BONE. OSTEOVATION WAS NOT SETTING IN A TIMELY MANNER AND THE SALES REPRESENTATIVE IN THE SURGERY TRIED TO CONTACT OSTEOMED SALES SUPPORT. THE PRODUCT MANAGER HELPED TROUBLESHOOT SOME STEPS TO HELP SETTING. WARM COMPRESSION WITH WARM SALINE FOR ABOUT 10 MINUTES WERE USED. THEN, LOWERED TUNICATE WAS USED TO INCREASE HEAT. OSTEOVATION BEGAN TO SET AND 2 DOCTORS MADE THE DECISION TO CLOSE AFTER THE OSTEOVATION WAS NO LONGER RUNNY. THE SALES REPRESENTATIVE SPOKE WITH THE DOCTOR IN (B)(6) 2020 AND THE DOCTOR REPORTED NO ISSUES WITH THE PATIENT OR PATIENT'S HEALING. IT WAS MENTIONED THAT ON X-RAYS WAS SHADOW NEAR THE OSTEOVATION IMPLANT SITE BUT FELT NO CONCERN WITH THE PRODUCT. PATIENT CALLED DOCTOR AND FOLLOWED UP IN OFFICE ON (B)(6) 2020 DUE TO OPEN WOUNDS AND TROUBLE HEALING. THE PHYSICIAN TREATED ROOMS AND REMOVED LIQUID AND WHAT APPEARED TO BE SOLID FRAGMENTS OF THE OSTEOVATION PRODUCT. THE DOCTOR CALLED THE SALES REPRESENTATIVE AFTER VISITING WITH PATIENT. THE DOCTOR INFORMED THAT THE PATIENT WAS PRESENTING WITH OPEN WOUNDS ON SURGICAL SITE AND HAD OBSERVED OSTEOVATION OOZING OUT OF WOUNDS. THE PATIENT HAD REMOVED SEVERAL REMNANTS OF OSTEOVATION AS WELL.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    429649 OSTEOVATION EX 5CC INJECT FORMULA BONE VOID FILLER PBU OSTEOMED, LLC 390-0005 1128523 00813845020023

    Patients

    Seq Age Sex Outcome Treatment
    1 68 YR Required Intervention